Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib and Capecitabine in Metastatic Pancreatic Cancer
NCT00962312Phase 2Completed
- Sponsor
- Cancer Trials Ireland
- Start
- Jan 2009
- Primary completion
- Dec 2010
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib and capecitabine in pancreatic cancer (PC), sponsored by Cancer Trials Ireland. Primary endpoint: 6-month survival rate. Started Jan 2009; status: completed.
02
Drugs
lapatinibcapecitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00962312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00962312.